Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1996-12-18
2002-03-19
Romeo, David S. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S328000, C530S858000, C424S405000, C424S198100
Reexamination Certificate
active
06358927
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to peptide fragments and analogs derived from the amino acid sequence of PBAN 1-33 NH
2
(PBAN=pheromone biosynthesis activating neuropeptide) showing stimulatory and inhibitory biological activities at doses similar to those of PBAN 1-33 (10-100 pmol). These peptide fragments serve as a basis for the design of insecticides aimed at the disruption of pheromone production, melanization and other activities controlled by PBAN 1-33 NH
2
and derived fragments.
Said invention further relates to a method for controlling adult female moths and insects by applying the above mentioned peptide fragments or peptidomimetic compounds derived from their sequence to any agricultural produce to inhibit pheromone production.
BACKGROUND OF THE INVENTION
Neuropeptides play a key role in the regulation of a variety of physiological functions in insects. These endocrine cues are involved in embryonic and post-embryonic developmental processes (such as molting, diapause and metamorphosis), in homeostasis, osmoregulation, diuresis and digestion. Insect neuropeptides are also known to control essential behavioral patterns such as migration, mating and oviposition. In recent years, the development of improved chemical, biochemical and molecular techniques has facilitated the identification of insect neuropeptides and resulted in the isolation and characterization of over fifty compounds.
Due to their substantial involvement in a variety of physiological processes, studies of insect neuropeptides introduce a new insight into basic life processes which may serve as an excellent basis for comparative neuroendocrine studies aimed to understand the evolutionary history of basic biological events. In addition, insect neuropeptides provide new targets for pest control which are based on the interference with their activity. This strategy requires a better understanding of the cascade of events common to the neuroendocrine regulation, namely: biosynthesis, release, transport, binding and activation of the target organ. So far, our understanding of these events for most insect neuropeptides is very limited. The present invention concentrates centrates on some of these aspects comprising the activity of peptide fragments derived from PBAN, which is known to regulate sex-pheromone biosynthesis and melanization in moths.
Sexual communication between male and female moths is regulated mainly by sex pheromones. Sex pheromones are synthesized and secreted by the female moth from the pheromone gland which is located at the intersegmental membrane between the eighth and the ninth abdominal segments. The inability of the female moth to produce sex pheromones results in a marked decrease in mating and thus, a significant reduction in the size of the population. Due to their important role in mating, sex pheromones have been studied intensively. In the past 30 years more than two hundred sex pheromones were isolated and identified. These studies revealed that moths sex pheromones consist of blends of C10-C18 aliphatic compounds, most of which have one or more double bonds. The diversity between pheromones of different species is indicated by differences in the chain length, the position and configuration of the olefinic bonds, and by the chemical nature of the functional group. Most pheromones are aldehydes, alcohols or acetates. Some, however, may-appear as epoxides, ketones and hydrocarbons.
While the structural and behavioral aspects of sex pheromones in Lepidopterans have been studied intensively, the endogenous mechanisms that control sex pheromone biosynthesis are not fully understood. The possible involvement of a cerebral factor in this process was first proposed in 1971 by Riddiford and Williams (Biol. Bull. 140, 1-7). Direct evidence of the involvement of a neuroendocrine factor in the regulation of sex pheromone biosynthesis was demonstrated for the first time only thirteen years later by Raina and Klun, (Science 225, 531-533, 1984) in
Helico-verpa zea
. The neuroendocrine factor was termed pheromone biosynthesis activating neuropeptide (PBAN), and since 1984 its presence has been demonstrated in a variety of moth species. Since its discovery PBAN was characterized as a linear C-terminally amidated peptide containing 33 amino acids. The primary structure of PBAN has been fully identified in two moth species:
Helicoverpa zea
and
Bombyx mori
and its gene and cDNA have been cloned from the same two insects. PBAN is synthesized in the subesophageal ganglion and is transported to its target organ via the hemolymph and/or the ventral nerve cord. It is present in both male and female moth and its biological activity is mediated by cAMP and depends on the presence of Ca
++
ions. In addition to its pheromonotropic activity PBAN and fragments derived from its sequence also control cuticular melanization, muscle contraction and diatause (for review see Altstein et al, Arch. Insect. Biochem. and Physiol. 22, 153-168, 1993; Raina, Ann. Rev. Entomol. 38, 329-349, 1993).
Despite the fact that PBAN has been studied for almost ten years, the understanding of its activity is quite limited, and most of the studies concentrate on: A) its release and transport; B) identification of its target organ; and C) its cellular activity. Among the various steps associated with the activity of the neuropeptide most effective and specific target for inhibition is the binding site of PBAN. Such an inhibition can be acquired by antagonists, which are selective inhibitors capable of locking the receptor site of the neuropeptide, and thus, preventing from the endogenous peptide to bind to the receptor and exert its biological activity. PBAN antagonists are, therefore, specific inhibitors for the production of sex pheromones. Since neuropeptides are chemically unstable and readily attacked by enzymes the strategy for the development of the antagonistic compounds is based on creating peptide-derived compounds (peptidomimetic compounds) which are biologically stable, and exhibit extended antagonistic activity. This strategy is novel and was never applied before for insect control.
In order to design peptidomimetic antagonists the structure-activity relationship of PBAN has to be revealed, and the active and inactive sequences in the molecule have to be identified. The main achievements of the study are:
A) The identification of the shortest fragment (six amino acids) derived from the sequence of Hez-PBAN that evokes pheromonotropic activity in the moth
Heliothis peltigera
at doses similar to those of Hez-PBAN 1-33 NH
2
(synthetic PBAN, based on the sequence of the peptide isolated from
Helicoveria zea
).
B) The identification of a 10 amino acid fragment derived from the original sequence of PBAN which exhibits partial antagonistic activity.
The finding that these two fragments are short peptides introduces the following advantages:
A) The number of possible derivatives that has to be screened in the course of the search for a potent antagonist is several orders of magnitude lower than the number that has to be screened in the case of a large peptide. This may shorten significantly the first stage of the search for a lead antagonist.
B) The production of a 10 or less amino acid pedtide is based on available equipment and technologies and is most efficient.
C) This finding is in line with the common practice in the insecticide industry that insecticides, particularly those applied to adult insects, should be of low molecular weight, in order to penetrate the insect's cuticle.
These achievements enable the application of strategies similar to those for rational drug design to search for peptidomimetic PBAN antagonists.
Two patent applications have been filed so far with respect to PBAN:
A) A Japanese patent application No. 4-208300 (Suzuki et. al) which relates to the full 33 amino acid sequence peptide isolated from silkworms, and also to some of its fragments. These peptides, according to this patent application are activating the pheromone bio-synthesis in silkworms. Th
Birch & Stewart Kolasch & Birch, LLP
Romeo David S.
State of Israel
LandOfFree
Peptide fragments and analogs derived from PBAN 1-33 NH2 for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide fragments and analogs derived from PBAN 1-33 NH2 for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide fragments and analogs derived from PBAN 1-33 NH2 for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2841968